Author

Dirk J. Reitsma

Observed names: D J Reitsma, D. J. Reitsma, D. Reitsma, Dirk J Reitsma, Dirk Reitsma

Observed institutions: Pharmaceutical Product Development (United States), The University of Texas MD Anderson Cancer Center, University of California, Los Angeles, Waikato Hospital, Dunedin Public Hospital, Massachusetts General Hospital, Novartis (United States), The Maria Sklodowska-Curie National Research Institute of Oncology, The University of Texas Health Science Center at Houston

OpenAlex ID: A5110967187

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

1996 · James R. Berenson, Alan Lichtenstein, et al. · New England Journal of Medicine · 1,070

Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone Metastases

1996 · Gabriel N. Hortobagyi, Richard L. Theriault, et al. · New England Journal of Medicine · 1,020

Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.

2001 · L S Rosen, D Gordon, et al. · PubMed · 895

Long‐term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma

2003 · Lee S. Rosen, David Gordon, et al. · Cancer · 869

PDF

Zoledronic Acid Versus Placebo in the Treatment of Skeletal Metastases in Patients With Lung Cancer and Other Solid Tumors: A Phase III, Double-Blind, Randomized Trial—The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group

2003 · Lee S. Rosen, David Gordon, et al. · Journal of Clinical Oncology · 726

Long‐term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors

2004 · Lee S. Rosen, David Gordon, et al. · Cancer · 706

PDF

Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases

2000 · Allan Lipton, Richard L. Theriault, et al. · Cancer · 661

Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group.

1998 · J R Berenson, A Lichtenstein, et al. · Journal of Clinical Oncology · 642

Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group.

1998 · G N Hortobagyi, R L Theriault, et al. · Journal of Clinical Oncology · 626

Pamidronate Reduces Skeletal Morbidity in Women With Advanced Breast Cancer and Lytic Bone Lesions: A Randomized, Placebo-Controlled Trial

1999 · Richard L. Theriault, Allan Lipton, et al. · Journal of Clinical Oncology · 597

The New Bisphosphonate, Zometa®(Zoledronic Acid), Decreases Skeletal Complications in Both Osteolytic and Osteoblastic Lesions: A Comparison to Pamidronate

2002 · Allan Lipton, E. Small, et al. · Cancer Investigation · 174

Phase Ib/II Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients with Advanced Solid Tumors

2017 · Vivek Subbiah, Juneko E. Grilley-Olson, et al. · Clinical Cancer Research · 121

Long-term complete remission inbladder carcinoma in situ with intravesical tice bacillus Calmette guerin

1991 · R. De Jager, E. Guinan, et al. · Urology · 86

2009 · Deirdre O'Mahony, John C. Morris, et al. · Clinical Cancer Research · 59

Quantitation of ineterferon-induced Mx protein in whole blood lysates by an immunochemiluminsescent assay: elimination of protease activity of cell lysates in toto

1994 · Se-Kyung Oh, Stefan Luhowskyj, et al. · Journal of Immunological Methods · 21

Challenges in the development of an autologous heat shock protein based anti-tumor vaccine

2012 · Dirk J. Reitsma, Austin J. Combest · Human Vaccines & Immunotherapeutics · 18

Alternative statistical strategies for biosimilar drug development

2014 · Austin J Combest, Song Wang, et al. · Generics and Biosimilars Initiative Journal · 10

PDF

PP-8-8 Reduction of skeletal related complications in breast cancer patients with osteolytic bone metastases receiving hormone therapy, by monthly pamidronate sodium (AREDIA®) infusion

1996 · R. Theriault, A. Upton, et al. · European Journal of Cancer · 9

Clinical remission of membranous glomerulonephritis in primary biliary cirrhosis with cutaneous vasculitis.

1984 · D J Reitsma, S Gratama, et al. · BMJ · 9

PDF

297 Preliminary phase I results of the oral, once-daily anglogenesis inhibitor PTK787/ZK 222584 (PTK/ZK) in combination with chemotherapy for the treatment of metastatic colorectal cancer

2003 · T. Trabach, A.L. Thomas, et al. · European Journal of Cancer Supplements · 8

Intravesical bacillus calmette-guérin and second primary malignancies

1989 · P. Guinan, S. Brosman, et al. · Urology · 6

Adult participation in oncology clinical trials by indication, race, and age.

2013 · Austin James Combest, Dirk J. Reitsma, et al. · Journal of Clinical Oncology · 4

Zometa® is effective and well tolerated in the prevention of skeletal related events secondary to metastatic breast cancer treated with hormonal therapy

2001 · R. Coleman, J. Apffelstaedt, et al. · European Journal of Cancer · 4

Inhibition of growth of human breast cancer cell lines with the combination of zoledronic acid and a COX-2 inhibitor

2001 · L. Witters, M. Javeed, et al. · European Journal of Cancer · 4

Phase Ib/II trial of NC-6004 (nanoparticle cisplatin) plus gemcitabine (G) in patients (pts) with advanced solid tumors

2016 · V. Subbiah, A. Combest, et al. · European Journal of Cancer · 3

Works count: 54

Citation count: 8,366

H-index: 16

I10-index: 17